159 related articles for article (PubMed ID: 34623791)
1. Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion
Ma P; Jin X; Fan Z; Wang Z; Yue S; Wu C; Chen S; Wu Y; Chen M; Gu D; Zhang S; Mao R; Fan Y
Cancer Biol Med; 2021 Oct; 19(5):669-84. PubMed ID: 34623791
[TBL] [Abstract][Full Text] [Related]
2. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
[TBL] [Abstract][Full Text] [Related]
3. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
4. Identifying a locus in super-enhancer and its resident NFE2L1/MAFG as transcriptional factors that drive PD-L1 expression and immune evasion.
Shi C; Chen L; Pi H; Cui H; Fan C; Tan F; Qu X; Sun R; Zhao F; Song Y; Wu Y; Chen M; Ni W; Qu L; Mao R; Fan Y
Oncogenesis; 2023 Nov; 12(1):56. PubMed ID: 37985752
[TBL] [Abstract][Full Text] [Related]
5. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
6. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.
Fan Z; Wu C; Chen M; Jiang Y; Wu Y; Mao R; Fan Y
Acta Pharm Sin B; 2022 Mar; 12(3):1041-1053. PubMed ID: 35530130
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1.
MacDonald WJ; Verschleiser B; Carlsen L; Huntington KE; Zhou L; El-Deiry WS
Am J Cancer Res; 2023; 13(7):2938-2947. PubMed ID: 37559982
[TBL] [Abstract][Full Text] [Related]
9. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
10. αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion.
Vannini A; Leoni V; Barboni C; Sanapo M; Zaghini A; Malatesta P; Campadelli-Fiume G; Gianni T
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20141-20150. PubMed ID: 31527243
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling.
Zhang Q; Yang Z; Hao X; Dandreo LJ; He L; Zhang Y; Wang F; Wu X; Xu L
Cell Biosci; 2023 Oct; 13(1):192. PubMed ID: 37848943
[TBL] [Abstract][Full Text] [Related]
13. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.
Zhang Y; Zhu S; Du Y; Xu F; Sun W; Xu Z; Wang X; Qian P; Zhang Q; Feng J; Xu Y
J Exp Clin Cancer Res; 2022 Feb; 41(1):66. PubMed ID: 35177112
[TBL] [Abstract][Full Text] [Related]
14. Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.
Raftery MJ; Abdelaziz MO; Hofmann J; Schönrich G
Front Immunol; 2018; 9():2560. PubMed ID: 30559738
[TBL] [Abstract][Full Text] [Related]
15. Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells.
Qu QX; Xie F; Huang Q; Zhang XG
Cell Physiol Biochem; 2017; 43(5):1893-1906. PubMed ID: 29055949
[TBL] [Abstract][Full Text] [Related]
16. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
17. KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma.
Gao Z; Chen JF; Li XG; Shi YH; Tang Z; Liu WR; Zhang X; Huang A; Luo XM; Gao Q; Shi GM; Ke AW; Zhou J; Fan J; Fu XT; Ding ZB
Cancer Cell Int; 2022 Mar; 22(1):128. PubMed ID: 35305624
[TBL] [Abstract][Full Text] [Related]
18. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
[TBL] [Abstract][Full Text] [Related]
19. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1.
Chen QH; Li B; Liu DG; Zhang B; Yang X; Tu YL
Cancer Cell Int; 2020; 20():394. PubMed ID: 32821247
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
